Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) shares gapped down before the market opened on Monday . The stock had previously closed at $10.51, but opened at $10.02. Arvinas shares last traded at $10.8210, with a volume of 394,353 shares.
More Arvinas News
Here are the key news stories impacting Arvinas this week:
- Positive Sentiment: Guggenheim reiterated a Buy on Arvinas, signaling confidence from a large institutional analyst that could support demand for the stock. Guggenheim Remains a Buy on Arvinas Holding Company (ARVN)
- Positive Sentiment: Barclays published a Buy on ARVN earlier this week, another supportive analyst view that may limit downside and attract investors focused on growth/clinical upside. Arvinas Holding Company (ARVN) Gets a Buy from Barclays
- Positive Sentiment: The FDA cleared a Pfizer/Arvinas breast cancer therapy despite mixed data; regulatory clearance is a material clinical and commercial milestone and supports longer‑term value if commercial rollout and label/usage expand. Note the “mixed data” caveat — clinical uptake and reimbursement remain key uncertainties. FDA clears Pfizer, Arvinas’ novel breast cancer therapy despite mixed data
- Neutral Sentiment: Arvinas scheduled its Q1 2026 earnings and corporate update webcast for May 12; this is a near‑term catalyst that could swing the stock depending on revenue, guidance, and clinical program updates. Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
- Neutral Sentiment: Media/analyst coverage pieces (Globe & Mail) discussed Arvinas alongside peers; increased attention can raise liquidity but does not by itself change fundamentals. Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN) and Axsome Therapeutics (AXSM)
- Negative Sentiment: HC Wainwright cut estimates across multiple quarters and years (FY2026–FY2030 and individual quarters), lowering near‑term EPS and pulling back some longer‑term optimism (notably big reductions for FY2026–FY2030). These downward revisions are likely the primary driver of today’s weaker price action, as they reduce near‑term earnings visibility and raise the bar for future upside. MarketBeat Arvinas Coverage (HC Wainwright estimates)
Analysts Set New Price Targets
A number of analysts recently issued reports on the company. Citigroup increased their price objective on Arvinas from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Monday. Truist Financial set a $10.00 price objective on Arvinas in a report on Wednesday, March 18th. Wedbush increased their price objective on Arvinas from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Tuesday, February 24th. Zacks Research cut Arvinas from a “hold” rating to a “strong sell” rating in a report on Monday, April 27th. Finally, Wall Street Zen cut Arvinas from a “hold” rating to a “sell” rating in a report on Monday, March 2nd. Nine investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, Arvinas presently has an average rating of “Hold” and an average target price of $14.60.
Arvinas Trading Down 3.3%
The firm has a fifty day simple moving average of $11.47 and a two-hundred day simple moving average of $11.67. The stock has a market cap of $661.98 million, a PE ratio of -8.02 and a beta of 1.79.
Arvinas (NASDAQ:ARVN – Get Free Report) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.55). Arvinas had a negative net margin of 30.77% and a negative return on equity of 14.25%. The business had revenue of $9.50 million during the quarter, compared to analysts’ expectations of $37.26 million. During the same period in the previous year, the business earned ($0.63) EPS. The business’s revenue was down 84.0% on a year-over-year basis. Equities analysts forecast that Arvinas, Inc. will post -3.25 earnings per share for the current year.
Insider Transactions at Arvinas
In related news, Director John G. Houston sold 35,297 shares of the firm’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $13.21, for a total transaction of $466,273.37. Following the transaction, the director directly owned 1,122,183 shares of the company’s stock, valued at approximately $14,824,037.43. This trade represents a 3.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Andrew Saik sold 5,134 shares of the firm’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $11.89, for a total value of $61,043.26. Following the transaction, the chief financial officer directly owned 159,267 shares in the company, valued at approximately $1,893,684.63. This represents a 3.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 63,864 shares of company stock worth $802,443. 4.73% of the stock is owned by insiders.
Hedge Funds Weigh In On Arvinas
A number of large investors have recently modified their holdings of ARVN. AQR Capital Management LLC purchased a new position in shares of Arvinas during the 1st quarter valued at about $727,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Arvinas during the 1st quarter valued at about $301,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Arvinas by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock valued at $271,000 after buying an additional 2,122 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Arvinas by 208.4% during the 1st quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock valued at $9,198,000 after buying an additional 885,483 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Arvinas by 108.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 902,925 shares of the company’s stock valued at $6,339,000 after buying an additional 469,394 shares in the last quarter. 95.19% of the stock is owned by hedge funds and other institutional investors.
Arvinas Company Profile
Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.
The company’s most advanced clinical candidates address hormone-driven cancers.
Recommended Stories
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.
